{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:25:06Z","timestamp":1790799906920,"version":"4.1.0"},"reference-count":33,"publisher":"Wiley","issue":"16","license":[{"start":{"date-parts":[[2011,2,24]],"date-time":"2011-02-24T00:00:00Z","timestamp":1298505600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2011,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>A phase 2 trial was conducted to determine the toxicity and efficacy of combined weekly topotecan and biweekly bevacizumab in patients with primary or secondary platinum\u2010resistant ovarian, peritoneal, or fallopian tube cancer (OC).<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>Patients were treated with bevacizumab 10 mg\/kg on days 1 and 15 and topotecan 4 mg\/m<jats:sup>2<\/jats:sup> on days 1, 8, and 15 of a 28\u2010day cycle until progressive disease (PD) or excessive toxicity. The primary endpoint was progression\u2010free survival (PFS); secondary objectives included overall survival (OS), objective response, and toxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Patients (N = 40) received a median of 8 treatment cycles. Toxicity was generally mild or moderate, with neutropenia (18%), hypertension (20%), gastrointestinal toxicity (18%), pain (13%), metabolic toxicity (15%), bowel obstruction (10%), and cardiotoxicity (8%) being the most common grade 3 and 4 adverse events. No bowel perforations, febrile neutropenia, or treatment\u2010related deaths occurred. Median PFS and OS were 7.8 (95% confidence interval [CI], 3.0\u20109.4) and 16.6 months (95% CI, 12.8\u201022.9), with 22 (55%) patients progression\u2010free for \u22656 months. Ten (25%) patients had partial response (PR), 14 (35%) had stable disease (SD), and 16 (40%) had PD. Patients treated with 2 prior regimens received greater benefit than patients treated with 1: PR\/SD, 78.9% versus 42.9% (<jats:italic>P<\/jats:italic> = .03); median PFS, 10.9 versus 2.8 months (<jats:italic>P<\/jats:italic> = .08); median OS, 22.9 versus 12.8 months (<jats:italic>P<\/jats:italic> = .02).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>A weekly topotecan and biweekly bevacizumab combination demonstrates acceptable toxicity and encouraging efficacy in patients with platinum\u2010resistant OC; further study is warranted. Cancer 2011;. \u00a9 2011 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.25967","type":"journal-article","created":{"date-parts":[[2011,2,26]],"date-time":"2011-02-26T10:10:18Z","timestamp":1298715018000},"page":"3731-3740","source":"Crossref","is-referenced-by-count":59,"title":["Combined weekly topotecan and biweekly bevacizumab in women with platinum\u2010resistant ovarian, peritoneal, or fallopian tube cancer"],"prefix":"10.1002","volume":"117","author":[{"given":"Kathryn F.","family":"McGonigle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard G.","family":"Muntz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Vuky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela J.","family":"Paley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan S.","family":"Veljovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin E.","family":"Greer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara A.","family":"Goff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi J.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W.","family":"Malpass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,2,24]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.02.553"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0020-7292(06)60033-7"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.8.14.2293"},{"key":"e_1_2_6_5_2","volume-title":"Avastin (bevacizumab) prescribing Information","author":"Genentech","year":"2009"},{"key":"e_1_2_6_6_2","doi-asserted-by":"crossref","first-page":"15s):946s. Abst","DOI":"10.1200\/jco.2010.28.18_suppl.lba1","article-title":"Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study [abstract]","volume":"28","author":"Burger RA","year":"2010","journal-title":"J Clin Oncol."},{"issue":"8","key":"e_1_2_6_7_2","first-page":"vii2","article-title":"ICON7: A phase III randomised Gynaecologic Cancer InterGroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC) [abstract]","volume":"21","author":"Perren T","year":"2010","journal-title":"Ann Oncol."},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.5345"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.0782"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.1939"},{"key":"e_1_2_6_11_2","doi-asserted-by":"crossref","first-page":"18s):284s. Abst","DOI":"10.1200\/jco.2009.27.15_suppl.5531","article-title":"A phase II evaluation of bevacizumab in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group (GOG) Study [abstract]","volume":"27","author":"Aghajanian C","year":"2009","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.9043"},{"key":"e_1_2_6_13_2","volume-title":"Hycamtin (topotecan hydrochloride) prescribing information","author":"GlaxoSmithKline","year":"2010"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2001.6435"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2004.08.026"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2006.11.017"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2007.08.062"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.02.028"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050997"},{"key":"e_1_2_6_20_2","first-page":"181","article-title":"Antiangiogenic effects of camptothecin analogues 9\u2010amino\u201020(S)\u2010camptothecin, topotecan, and CPT\u201011 studied in the mouse cornea model","volume":"5","author":"O'Leary JJ","year":"1999","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.01.223"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.6735"},{"key":"e_1_2_6_23_2","first-page":"203a","article-title":"A phase III study of Doxil\/Caelyx versus paclitaxel in platinum\u2010treated, taxane\u2010naive relapsed ovarian cancer [abstract]","volume":"21","author":"O'Byrne KJ","year":"2002","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.14.3312"},{"key":"e_1_2_6_25_2","volume-title":"Preliminary efficacy and safety of pegylated liposomal doxorubicin and bevacizumab in patients with platinum resistant or intolerant ovarian cancer: Initial results of a phase 2 trial. Presented at: International Gynecologic Cancer Society 12th Biennial Meeting","author":"Verschraegen C","year":"2008"},{"key":"e_1_2_6_26_2","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2009.27.15_suppl.5547","article-title":"Effects of weekly bevacizumab and pegylated liposomal doxorubicin in heavily pretreated patients with recurrent or progressed ovarian cancer [abstract]","volume":"27","author":"Kikuchi Y","year":"2009","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2010.01.011"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70112-3"},{"key":"e_1_2_6_29_2","first-page":"S57","article-title":"Bevacizumab and weekly topotecan as salvage chemotherapy for ovarian cancer [abstract]","volume":"112","author":"Seamon LG","year":"2009","journal-title":"Gynecol Oncol."},{"key":"e_1_2_6_30_2","doi-asserted-by":"crossref","unstructured":"SfakianosGP NumnumTM HalversonCB PanjetiD KendrickJEIV StraughnJMJr.The risk of gastrointestinal perforation and\/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: A retrospective cohort study. Gynecol Oncol.2009;114:424\u2010426.","DOI":"10.1016\/j.ygyno.2009.05.031"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70362-6"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn729"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-009-9104-9"},{"key":"e_1_2_6_34_2","doi-asserted-by":"crossref","first-page":"242s","DOI":"10.1200\/jco.2010.28.15_suppl.3039","article-title":"Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV) [abstract]","volume":"28","author":"Hurwitz H","year":"2010","journal-title":"J Clin Oncol."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.25967","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.25967","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T16:04:52Z","timestamp":1760285092000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.25967"}},"subtitle":["Results of a Phase 2 Study"],"short-title":[],"issued":{"date-parts":[[2011,2,24]]},"references-count":33,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2011,8,15]]}},"alternative-id":["10.1002\/cncr.25967"],"URL":"https:\/\/doi.org\/10.1002\/cncr.25967","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,24]]}}}